Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myelodysplasia and liver disease extend the spectrum of RTEL1 related telomeropathies.
Cardoso SR, Ellison ACM, Walne AJ, Cassiman D, Raghavan M, Kishore B, Ancliff P, Rodríguez-Vigil C, Dobbels B, Rio-Machin A, Al Seraihi AFH, Pontikos N, Tummala H, Vulliamy T, Dokal I. Cardoso SR, et al. Among authors: kishore b. Haematologica. 2017 Aug;102(8):e293-e296. doi: 10.3324/haematol.2017.167056. Epub 2017 May 11. Haematologica. 2017. PMID: 28495916 Free PMC article. No abstract available.
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C. Nikolousis E, et al. Among authors: kishore b. Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5. Leuk Res. 2013. PMID: 23395505 Clinical Trial.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Allotey D, Shafeek S, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Clinical Studies Group UNHO. Jackson GH, et al. Among authors: kishore b. Haematologica. 2021 Jul 1;106(7):1957-1967. doi: 10.3324/haematol.2020.247130. Haematologica. 2021. PMID: 32499244 Free PMC article. Clinical Trial.
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.
Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia M, Huerta AJ, Nloga AM, González-Sanmiguel JD, Schmidt A, Lambert JF, Lehmann S, Di Bona E, Cassinat B, Hofmann WK, Görlich D, Sauerland MC, Fenaux P, Sanz M; European LeukemiaNet. Lengfelder E, et al. Among authors: kishore b. Leukemia. 2015 May;29(5):1084-91. doi: 10.1038/leu.2015.12. Epub 2015 Jan 28. Leukemia. 2015. PMID: 25627637
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Kanellopoulos A, Kaparou M, Xenou E, Paneesha S, Kishore B, Lovell R, Holder K, Suhr J, Baker L, Ryan L, Nikolousis E. Kanellopoulos A, et al. Among authors: kishore b. Bone Marrow Transplant. 2018 Dec;53(12):1518-1521. doi: 10.1038/s41409-018-0297-z. Epub 2018 Aug 16. Bone Marrow Transplant. 2018. PMID: 30116019
Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.
Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F. Galleu A, et al. Among authors: kishore b. Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13. Br J Haematol. 2019. PMID: 30637732 Free PMC article.
A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant.
Horgan C, Kanellopoulos A, Paneesha S, Kishore B, Lovell R, Nikolousis E. Horgan C, et al. Among authors: kishore b. Hematol Rep. 2019 Feb 25;11(1):7800. doi: 10.4081/hr.2019.7800. eCollection 2019 Feb 19. Hematol Rep. 2019. PMID: 30915202 Free PMC article.
Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
Horgan C, Elmoamly S, McIlroy G, Davies D, Kaparou M, Giles H, Xenou E, Kishore B, Lovell R, Nikolousis E, Shankara P, Kanellopoulos A. Horgan C, et al. Among authors: kishore b. Leuk Lymphoma. 2019 Dec;60(12):3075-3077. doi: 10.1080/10428194.2019.1607323. Epub 2019 May 13. Leuk Lymphoma. 2019. PMID: 31079514 No abstract available.
Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.
McIlroy G, Nikolousis E, Abou-Zeid N, Shankara P, Kishore B, Kaparou M, Lovell R, Elmoamly S, Davies D, Horgan C, Shenouda A, Kanellopoulos A. McIlroy G, et al. Among authors: kishore b. Leuk Lymphoma. 2020 Jan;61(1):202-205. doi: 10.1080/10428194.2019.1650177. Epub 2019 Aug 11. Leuk Lymphoma. 2020. PMID: 31402762 No abstract available.
218 results